Pembrolizumab/Vibostolimab coformulation for Prostate Cancer
This study is evaluating whether a combination of drugs may help treat prostate cancer.
See full descriptionAbout the trial for Prostate Cancer
Treatment Groups
This trial involves 10 different treatments. Pembrolizumab/Vibostolimab Coformulation is the primary treatment being studied. Participants will be divided into 10 treatment groups. There is no placebo group. The treatments being tested are in Phase 1 & 2 and have already been tested with other people.
About The Treatment
Eligibility
This trial is for male patients aged 18 and older. You must have received newly diagnosed for Prostate Cancer or the other condition listed above. There are 10 eligibility criteria to participate in this trial as listed below.
Approximate Timelines
Measurement Requirements
This trial is evaluating whether Pembrolizumab/Vibostolimab coformulation will improve 4 primary outcomes and 8 secondary outcomes in patients with Prostate Cancer. Measurement will happen over the course of Assessed Over the Duration of the Study Which is Estimated to be Approximately 2 Years.
Patient Q & A Section
What causes prostate cancer?
Over half of [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer)s occur in men under 50 who are younger than their fathers, and those men are twice as likely to be diagnosed before the age of 50. This suggests that certain environmental factors are accountable for prostate cancer at all ages. The higher levels of prostate-specific antigen (PSA) observed in men of advanced ages may indicate an increased risk of prostate cancer.
How many people get prostate cancer a year in the United States?
Approx. 6,500 men are confirmed to have prostate cancer each year in the United States, making up approximately 1.3% of all men at risk for having prostate cancer. This number includes 1,100 men with Gleason > or = 8 prostate cancer, 1,000 men with pT1 prostate cancer, and 2,000 men with cN0 prostate cancer.
What are the signs of prostate cancer?
There is usually no one specific sign of prostate cancer. However, the symptoms associated with prostate cancer may lead to its identification and diagnosis early.
What are common treatments for prostate cancer?
A variety of treatments are employed for prostate cancer, including medication, and the use of surgery and other treatment modalities. The most common treatment for prostate cancer depends on the disease stage and the aggressiveness of the tumor. A treatment decision based on the person's condition and needs may also be important.
Can prostate cancer be cured?
In more localized [prostate cancer](https://www.withpower.com/clinical-trials/prostate-cancer)s, treatment has improved to a level where treatment can reduce symptoms, prolong survival and prevent cancer death. However, in more aggressive disease the ability to cure prostate cancer has been reduced to near death levels. It seems likely that advances in treatment for aggressive disease will continue, and prostate cancer death will continue to fall. Even though patients are able to live a good life, this will never be the case when treatment is not available. Thus, the treatment of prostate cancer cannot be cured.
What is prostate cancer?
Prostate cancer is currently the 7th-most-common cancer to be diagnosed in men in the United States, accounting for approximately 9.1% of all cases. The vast majority of prostate cancer cases occur in men over 50, which presents many problems in terms of healthcare and patient care. This is also why prostate cancer was selected as a subject for this lecture.\n
What is pembrolizumab/vibostolimab coformulation?
In this first line phase III multicenter trial, PD-1 immune checkpoint antibody, plus vb, did not demonstrate superiority over mb in patients with metastatic melanoma. Pembrolizumab plus vibostolimab in patients with advanced melanoma is currently being investigated in a large international multicenter phase 3 clinical trial (ADEPT-IL2-IL13 or ADEPT trial).
Does pembrolizumab/vibostolimab coformulation improve quality of life for those with prostate cancer?
In this exploratory analysis, prostate cancer patients treated with pembrolizumab/vibostolimab coformulation had less nausea, vomiting, fatigue, and anxiety but no more serious adverse events or pain when compared to monotherapy with pembrolizumab/vibostolimab. Further studies are needed to clarify whether the combination is superior to pembrolizumab/vibostolimab for improving quality of life in prostate cancer patients.
What is the average age someone gets prostate cancer?
The average age that men are diagnosed with prostate cancer is approximately 72.4 years. This varies geographically, as the average age of diagnosed prostate cancer is highest in British Columbia at 73 years of age and lowest in Mississippi at 70.7 years.
Who should consider clinical trials for prostate cancer?
The vast majority of men with clinically localized prostate cancer are not likely to benefit from enrollment in a clinical research trial. Physicians should be aware that current research trials are only designed for treatment arms with a high probability of cure. Physicians should refrain from discouraging patients with prostate cancer because they are unlikely to have a cure.
Is pembrolizumab/vibostolimab coformulation safe for people?
These data show the potential for a safer formulation. Pembrolizumab/vibostolimab coformulation had a less favorable safety profile and lower antitumor activity than either pembrolizumab or vibostolimab alone.
What are the common side effects of pembrolizumab/vibostolimab coformulation?
The combination of pembrolizumab/vibostolimab shows a broad spectrum of treatment-related side effects, including fatigue, nausea, headache, and fatigue. Patients are encouraged to monitor weight and blood levels of calcium and phosphorus.